Clinical outcomes of curative treatment for colorectal liver metastases combined with cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases: a systematic review and meta-analysis of current evidence

Zou, Yifeng; Chen, Xi; Zhang, Xinzhi; Shen, Zhihong; Cai, Jiawei; Tan, Yongtao; Weng, Jing-rong; Rong, Yuming; Lin, Xutao

doi:10.1080/02656736.2020.1803424

Cited by 5 publications

(2 citation statements)

References 36 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent meta-analysis, the median OS for CRAdenoCa peritonectomy patients without sLM ranged from 21 to 65 months, which is approximately consistent with the median OS of 20 months for this cohort in our study (15). For AAdenoCa patients without sLM, no specific survival studies have been performed.…”

Section: Discussionsupporting

confidence: 89%

Increased Incidence of Liver Metastases in ColorectalVersusAppendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival

GARRETT,

CRISTAUDO,

BARAT

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: Colorectal adenocarcinoma (CRAdenoCa) and appendiceal adenocarcinoma (AAdenoCa) are diseases of the same histopathological type that metastasise to the liver and peritoneum. In selected subgroups, peritonectomy and heated intraperitoneal chemotherapy (HIPEC) may be indicated as part of the multimodal treatment plan. However, literature comparing the survival outcomes and preoperative tumour activity and burden of CRAdenoCa and AAdenoCa peritonectomy patients without synchronous liver metastases (sLM) is scarce. Little is also known about the comparative incidence of sLM and metachronous LM (mLM) between CRAdenoCa and AAdenoCa peritonectomy patients. This study aimed to clarify the above. Patients and Methods: A retrospective cohort study of 684 CRAdenoCa and AAdenoCa primary peritonectomy patients between 2001-2021 was conducted at St George Hospital in Sydney, Australia. Results: Median overall survival (years) was equivocal between CRAdenoCa and AAdenoCa peritonectomy patients (1.7 vs. 1.9, p=0.35). Peritoneal cancer index and preoperative carcinoembryonic antigen (CEA) were significantly elevated (25 vs. 9, p<0.0001 and 7.9 vs. 5, p=0.0080) in AAdenoCa versus CRAdenoCa peritonectomy patients without sLM. The incidence of sLM and mLM was increased in CRAdenoCa peritonectomy patients (24% vs. 3.1%, p<0.0001 and 26% vs. 10%, p=0.0001). Conclusion: This study demonstrates similar survival outcomes between CRAdenoCa and AAdenoCa peritonectomy patients.Despite elevated preoperative tumour burden and biological activity in AAdenoCa patients, CRAdenoCa patients had higher rates of sLM and mLM. Further studies are warranted to validate and identify cellular and molecular targets that increase CRAdenoCa's ability to metastasise to the liver.

show abstract

Section: Discussionsupporting

confidence: 89%

Increased Incidence of Liver Metastases in ColorectalVersusAppendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival

GARRETT,

CRISTAUDO,

BARAT

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

show abstract

“…Despite the feasibility and safety of the combined LR and CRS–HIPEC in metastatic CRC reported from several studies ( 20 , 22 , 23 , 27 , 33 , 36 , 37 , 39 , 45 ), data on the matter show conflicting results, with updated studies and meta-analyses demonstrating evidence to the contrary ( 5 , 21 , 32 , 34 , 46 ). Razenberg et al ( 47 ) reported a significantly lower median OS in patients with concomitant PC + LM treated with palliative chemotherapy compared to the patients treated with CRS and HIPEC (12.5 vs. 23.1 months). However, there could be a biased selection in interpreting this result as no data regarding the two groups (dissemination of the disease, history prior to treatment, and general conditions of the patients) were available.…”

Section: Discussionmentioning

confidence: 99%

Synchronous liver and peritoneal metastases from colorectal cancer: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?

et al. 2022

View full text Add to dashboard Cite

BackgroundTraditionally, synchronous liver resection (LR), cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy for colorectal liver and peritoneal metastases have been contraindicated. Nowadays, clinical practice has promoted this aggressive treatment in selected cases. This study aimed to review surgical and survival results of an extensive surgical approach including CRS with hyperthermic intraperitoneal chemotherapy (HIPEC) and LR.MethodsPubMed, EMBASE, and Web of Science databases were matched to find the available literature on this topic. The search period was limited to 10 years (January 2010–January 2021). A threshold of case series of 10 patients or more was applied.ResultsIn the search period, out of 114 studies found about liver and peritoneal metastases from colorectal cancer, we found 18 papers matching the inclusion criteria. Higher morbidity and mortality were reported for patients who underwent such an extensive surgical approach when compared with patients who underwent only cytoreductive surgery and HIPEC. Also, survival rates seem worse in the former than in the latter.ConclusionThe role of combined surgical strategy in patients with synchronous liver and peritoneal metastases from colorectal cancer remains controversial. Survival rates and morbidity and mortality seem not in favor of this option. A more accurate selection of patients and more restrictive surgical indications could perhaps help improve results in this subgroup of patients with limited curative options.

show abstract

Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence

Grange,

Rousset,

Williet

et al. 2024

Ann Surg Oncol

View full text Add to dashboard Cite

Clinical outcomes of curative treatment for colorectal liver metastases combined with cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases: a systematic review and meta-analysis of current evidence

Abstract: View related articles View Crossmark data Clinical outcomes of curative treatment for colorectal liver metastases combined with cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases: a systematic review and meta-analysis of current evidence

Cited by 5 publications

References 36 publications

Increased Incidence of Liver Metastases in ColorectalVersusAppendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival

Increased Incidence of Liver Metastases in ColorectalVersusAppendiceal Adenocarcinoma Peritonectomy Patients Despite Equivocal Survival

Synchronous liver and peritoneal metastases from colorectal cancer: Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?

Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence

Contact Info

Product

Resources

About